Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
Continue reading "Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy"